EGFR and non-small cell lung carcinoma: Icotinib is a first-generation EGFR-TKIs approved by the National Medical Products Administration of China (NMPA) and is currently only available in China for the treatment of EGFR 19-deletion or L858R-mutated NSCLC, with a similar molecular structure to two first-generation EGFR-TKIs (GEF and erlotinib) (21).